One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

August 5, 2025

Conditions
Lung CancerOligometastatic Lung Tumor
Interventions
RADIATION

One fraction stereotactic body radiotherapy

Radiotherapy will consist of one-fraction SBRT using the Ethos linear accelerator and online adaptive treatment planning system.

DEVICE

HyperSight

HyperSight is a novel on-board imaging platform equipped with rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for both simulation and treatment.

DEVICE

Ethos

Ethos is a unique ring-gantry CT-guided linear accelerator notable for having a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Varian Medical Systems

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT06236516 - One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors | Biotech Hunter | Biotech Hunter